Royal Bank of Canada Purchases 179,418 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Royal Bank of Canada increased its position in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 479.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 216,861 shares of the company’s stock after purchasing an additional 179,418 shares during the quarter. Royal Bank of Canada’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $4,893,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FMS. CIBC Private Wealth Group LLC boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after purchasing an additional 1,103 shares during the last quarter. Arax Advisory Partners raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 121.6% during the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after buying an additional 885 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the fourth quarter worth approximately $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA in the fourth quarter valued at approximately $58,000. Finally, Group One Trading LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA in the third quarter valued at approximately $74,000. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.7%

Shares of NYSE:FMS opened at $23.71 on Thursday. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $20.02 and a 52 week high of $27.64. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07. The company has a market capitalization of $12.74 billion, a PE ratio of 12.28, a PEG ratio of 4.43 and a beta of 0.77. The company has a 50 day moving average price of $23.78 and a two-hundred day moving average price of $23.07.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. The company had revenue of $5.55 billion for the quarter, compared to analysts’ expectations of $5.48 billion. Analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.25 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on FMS. Truist Financial set a $25.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, August 5th. BNP Paribas Exane downgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price target on the stock. in a research note on Tuesday, July 28th. Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Sanford C. Bernstein lifted their price objective on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 4th. Six research analysts have rated the stock with a Hold rating and five have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $23.57.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.